Helse Bergen HF
Helse Bergen HF is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA)
Sponsor Region Skane
- Start (EU)
- Latest update
- Estimated end
TRIANGLE - autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European mcl network trial
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Helse Bergen HF?
The 2026-10-09 snapshot links Helse Bergen HF to 2 distinct CTIS trials. Recorded services include Clinical monitoring. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Helse Bergen HF?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Helse Bergen HF conducted?
The linked trials record locations in 12 countries, including Denmark, Finland, Norway, Sweden, Belgium. These are trial locations, not confirmed office locations or countries where Helse Bergen HF delivered services.
What can this page tell me about Helse Bergen HF's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Helse Bergen HF. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Helse Bergen HF